https://metabolicwire.com/ daily 1.0 https://metabolicwire.com/category/glp-1-news daily 0.8 https://metabolicwire.com/category/metabolic-science daily 0.8 https://metabolicwire.com/category/patient-stories daily 0.8 https://metabolicwire.com/category/diet-and-nutrition daily 0.8 https://metabolicwire.com/category/research daily 0.8 https://metabolicwire.com/category/policy-and-access daily 0.8 https://metabolicwire.com/article/2026-08-13-popular-glp-1-weight-loss-drugs-linked-to-30-lower-breast-cancer-risk weekly 0.6 https://metabolicwire.com/article/2026-08-12-eli-lilly-files-first-lawsuits-over-retatrutide-black-market weekly 0.6 https://metabolicwire.com/article/2026-08-12-do-glp-1s-belong-in-dermatology-evidence-suggests-a-growing-role weekly 0.6 https://metabolicwire.com/article/2026-08-10-new-study-may-change-how-we-think-about-glp-1s weekly 0.6 https://metabolicwire.com/article/2026-08-10-uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-di weekly 0.6 https://metabolicwire.com/article/2026-08-10-uk-approves-its-second-weight-loss-pill-while-eu-access-lags weekly 0.6 https://metabolicwire.com/article/2026-08-11-a-hybrid-lifestyle-program-and-metabolic-health-in-adults-with-obesity weekly 0.6 https://metabolicwire.com/article/2026-08-07-the-oral-glp-1-tracker-lilly-s-foundayo-builds-scripts-after-disappointing-q2 weekly 0.6 https://metabolicwire.com/article/2026-08-06-the-divide-between-eli-lilly-and-novo-nordisk-is-widening-after-their-latest-ear weekly 0.6 https://metabolicwire.com/article/2026-08-05-eli-lilly-easily-tops-quarterly-estimates-raises-outlook-as-zepbound-and-mounjar weekly 0.6 https://metabolicwire.com/article/2026-08-05-novo-nordisk-ceo-defends-economics-of-wegovy-pill-as-lower-prices-weigh-on-sales weekly 0.6 https://metabolicwire.com/article/2026-08-05-glp-1-drugs-may-reshape-not-replace-bariatric-surgery weekly 0.6 https://metabolicwire.com/article/2026-08-04-novo-nordisk-shares-slide-after-guidance-disappoints-investors weekly 0.6 https://metabolicwire.com/article/2026-08-01-analysis-of-19-trials-finds-glp-1-results-differ-by-drug-and-dose-pointing-towar weekly 0.6 https://metabolicwire.com/article/2026-07-30-lilly-s-obesity-pill-foundayo-gains-early-blockbuster-forecast-as-analysts-float weekly 0.6 https://metabolicwire.com/article/2026-07-28-novo-lilly-tout-respective-early-response-and-weight-loss-maintenance-data-as-gl weekly 0.6 https://metabolicwire.com/article/2026-07-24-tga-issues-warning-over-glp-1-based-drugs-potential-to-cause-rare-eye-disorder weekly 0.6 https://metabolicwire.com/article/2026-07-24-novo-s-ozempic-copy-15-cheaper-but-discovery-still-won-t-change-its-position weekly 0.6 https://metabolicwire.com/article/2026-07-23-lilly-s-triple-agonist-heads-to-regulators-after-two-more-phase-3-obesity-wins weekly 0.6 https://metabolicwire.com/article/2026-07-22-availability-of-generic-semaglutide-removes-barrier-to-affordable-diabetes-care- weekly 0.6 https://metabolicwire.com/article/2026-07-21-novo-nordisk-sues-eli-lilly-over-glp-1-drug-ads-it-calls-deceptive weekly 0.6 https://metabolicwire.com/article/2026-07-21-novo-nordisk-sues-eli-lilly-over-glp-1-ads weekly 0.6 https://metabolicwire.com/article/2026-07-19-orforglipron-pill-beats-oral-semaglutide-in-major-diabetes-trial weekly 0.6 https://metabolicwire.com/article/2026-07-15-novo-nordisk-receives-european-commission-approval-of-wegovy-pill-as-first-oral- weekly 0.6 https://metabolicwire.com/article/2026-07-09-medicare-prescriptions-for-wegovy-spike-after-heart-disease-coverage-expansion weekly 0.6 https://metabolicwire.com/article/2026-07-01-medicare-is-now-covering-some-glp-1-weight-loss-drugs-for-50-here-s-what-to-know weekly 0.6 https://metabolicwire.com/article/2026-06-30-the-loophole-in-trump-s-obesity-drug-deal-with-eli-lilly-and-novo-nordisk weekly 0.6 https://metabolicwire.com/article/2026-06-24-u-s-health-spending-rose-sharply-in-2025-thanks-to-glp-1-use-and-more-care weekly 0.6 https://metabolicwire.com/article/2026-06-23-eli-lilly-gave-extraordinary-obesity-drug-access-to-a-79-year-old-patient-who-wa weekly 0.6 https://metabolicwire.com/article/2026-06-18-what-s-next-for-glp-1-weight-loss-drugs weekly 0.6 https://metabolicwire.com/article/2026-06-15-trump-s-obesity-drug-plan-creates-a-temporary-medicare-program-that-may-be-hard- weekly 0.6 https://metabolicwire.com/article/2026-06-09-ada-lilly-bests-novo-again-takes-glp-1-pill-foundayo-to-fda-for-diabetes-approva weekly 0.6 https://metabolicwire.com/article/2026-06-08-astrazeneca-s-glp-1-pill-shows-promise-in-obesity-diabetes-trials weekly 0.6 https://metabolicwire.com/article/2026-06-08-achieve-trials-demonstrate-comparative-benefits-of-novel-small-molecule-oral-glp weekly 0.6 https://metabolicwire.com/article/2026-06-07-ada26-19-of-phase-3-patients-quit-boehringer-obesity-shot-over-side-effects weekly 0.6 https://metabolicwire.com/article/2026-05-28-cvs-restores-zepbound-coverage-adds-eli-lilly-s-obesity-pill-foundayo weekly 0.6 https://metabolicwire.com/article/2026-05-29-tirzepatide-raises-thyroid-risk-in-certain-at-risk-patients weekly 0.6 https://metabolicwire.com/article/2026-05-21-eli-lilly-weight-loss-drug-retatrutide-clears-obesity-trial weekly 0.6 https://metabolicwire.com/article/2026-05-21-lilly-s-triple-agonist-still-leads-among-late-stage-obesity-assets weekly 0.6 https://metabolicwire.com/article/2026-05-13-wegovy-pill-delivered-21-6-weight-loss-in-early-responders-and-doubled-mobility- weekly 0.6 https://metabolicwire.com/article/2026-05-06-novo-nordisk-q1-2026-earnings-wegovy-sales-jump weekly 0.6 https://metabolicwire.com/article/2026-04-30-fda-proposes-excluding-novo-lilly-glp-1s-from-compounding-list weekly 0.6 https://metabolicwire.com/article/2026-04-22-restrictions-on-obesity-drug-coverage-force-patients-to-pivot weekly 0.6 https://metabolicwire.com/article/2026-04-22-trump-admin-shifts-course-on-medicare-glp-1-coverage weekly 0.6 https://metabolicwire.com/article/2026-04-17-fructose-emerges-as-a-key-driver-of-metabolic-disease weekly 0.6 https://metabolicwire.com/article/2026-04-07-novo-undercuts-lilly-with-high-dose-wegovy-at-399-a-month weekly 0.6 https://metabolicwire.com/article/2026-04-06-glp-1-agonist-drugs-show-digestive-side-effects-but-may-help-fight-infections weekly 0.6 https://metabolicwire.com/article/2026-04-01-fda-approves-lilly-s-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-t weekly 0.6 https://metabolicwire.com/article/2026-04-01-fda-approves-lilly-s-oral-glp-1-orforglipron-for-obesity weekly 0.6 https://metabolicwire.com/article/2026-04-01-eli-lilly-gets-speedy-fda-nod-for-oral-glp-1-drug-a-competitor-to-new-novo-nordi weekly 0.6 https://metabolicwire.com/article/2026-03-31-weight-loss-jab-wegovy-to-be-offered-on-nhs-for-people-at-risk-of-further-heart- weekly 0.6 https://metabolicwire.com/article/2026-03-31-novo-nordisk-india-cuts-prices-on-ozempic-wegovy-to-counter-generic-rivals weekly 0.6 https://metabolicwire.com/article/2026-03-20-health-rounds-diabetes-patients-who-stop-glp-1-drugs-increase-their-heart-risks weekly 0.6 https://metabolicwire.com/article/2026-03-19-weight-loss-treatment-is-on-the-verge-of-a-dramatic-shift-again weekly 0.6 https://metabolicwire.com/article/2026-03-18-heart-benefits-fade-after-stopping-glp-1-medications-study-finds weekly 0.6 https://metabolicwire.com/article/2026-03-17-fda-novo-nordisk-failed-to-report-deaths-of-weight-loss-drug-patients weekly 0.6 https://metabolicwire.com/article/2026-03-16-ozempic-patent-expiry-heralds-weight-loss-drug-boom-in-india weekly 0.6 https://metabolicwire.com/article/2026-03-10-glp-1-receptor-agonist-switching-and-treatment-persistence-in-adults-without-dia weekly 0.6 https://metabolicwire.com/article/2026-03-03-aspen-pharmacare-expects-canada-entry-with-ozempic-generic-by-third-quarter weekly 0.6